ArticleNature communications2026
Engineering non-exponential proliferation in Escherichia coli using functionalized protein aggregates.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering non-exponential proliferation in Escherichia coli using functionalized protein aggregates.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Microbes naturally grow exponentially, but this trait might not always be desirable for applications with genetically modified microorganisms. Especially in microorganisms engineered for therapeutic applications, uncurbed exponential proliferation might cause unpredictable liabilities in their behavior that in turn compromise their dosing and biocontainment. In an effort to fundamentally reprogram population growth dynamics, we constructed a bacterial chassis that adheres to linear proliferation for a finite number of generations. More specifically, growth of the chassis is directed by an intracellular protein aggregate that is engineered to reconstitute a split enzyme producing cAMP as a conditionally essential metabolite. Due to the asymmetric segregation and gradual disaggregation of this aggregate, it autonomously keeps growth restricted to the aggregate inheriting cell and to a limited number of divisions. By imposing such a transient and linear growth potential without the need for external intervention, this chassis offers a unique venue for the controlled application of engineered microorganisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.